Predictors of Incident High-Risk Varices in Patients with Hepatitis B-Related Cirrhosis Receiving Nucleos(t)ide Analog Therapy
Digestive Diseases · 16.07.2026 · 1-10
DOI: 10.1159/000553519 ↗Kurz gefasst
Fachartikel in der Zeitschrift Digestive Diseases, online erschienen am 16.07.2026. Verfasst von Yu-Chia Chiu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan. Hauptthemen laut MEDLINE: Liver Cirrhosis, Esophageal and Gastric Varices, Hepatitis B, Chronic, Nucleosides. Die Arbeit nennt 34 Literaturangaben.
Abstract (Originalsprache)
Introduction
In patients receiving nucleos(t)ide analog (NA) therapy for chronic hepatitis B (CHB)-related cirrhosis, routine endoscopic surveillance may be deferred in the absence of high-risk varices (HRV). We aimed to identify predictors of incident HRV in this population.
Methods
This retrospective cohort study included patients with CHB-related cirrhosis who initiated NA therapy between March 2008 and June 2020 and were followed through May 2024. Eligible patients underwent baseline and on-treatment upper endoscopy. Patients with baseline HRV, prior variceal ligation, use of nonselective β-blockers, other viral hepatitis, alcohol overuse, or malignancy were excluded. The cumulative incidence of HRV and adjusted subdistribution hazard ratios (aSHRs) were estimated using competing-risk methods. A point-based risk prediction model was derived from multivariable regression coefficients.
Results
Among the 110 included patients, 14 (12.7%) developed HRV over a median follow-up of 3.6 years (IQR, 2.0–5.6). In multivariable analysis, fibrosis-4 (FIB-4) ≥4.0 (aSHR 9.77; 95% CI, 1.45–65.7), coexisting metabolic dysfunction-associated steatotic liver disease (MASLD) (aSHR 6.37; 95% CI, 1.84–22.0), and albumin-bilirubin (ALBI) grade >1 (aSHR 3.02; 95% CI, 1.21–7.55) were independently associated with incident HRV and were assigned 3, 2, and 1 point, respectively, in the prediction model. At 3 years, the cumulative incidence of HRV was 1.5% (95% CI, 0–4.5) in the low-risk group (0–3 points) and 21.4% (95% CI, 8.0–34.8) in the high-risk group (4–6 points) (p = 0.001).
Conclusion
MASLD, FIB-4, and ALBI grade predict incident HRV in NA-treated CHB cirrhosis, enabling risk-stratified endoscopic surveillance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.
- Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan.
- School of Medicine, Chung Shan Medical University, Taichung, Taiwan.
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan, tylee@vghtc.gov.tw.
- School of Medicine, Chung Shan Medical University, Taichung, Taiwan, tylee@vghtc.gov.tw.
Zitieren
APA
Chiu, Y. C., Tsai, H. J., Chen, C. C., Lin, Y. C., Lee, S. W., & Lee, T. Y. (2026). Predictors of Incident High-Risk Varices in Patients with Hepatitis B-Related Cirrhosis Receiving Nucleos(t)ide Analog Therapy. Digestive Diseases, 1-10. https://doi.org/10.1159/000553519
Vancouver
Chiu YC, Tsai HJ, Chen CC, Lin YC, Lee SW, Lee TY. Predictors of Incident High-Risk Varices in Patients with Hepatitis B-Related Cirrhosis Receiving Nucleos(t)ide Analog Therapy. Digestive Diseases. 2026:1-10. doi:10.1159/000553519
BibTeX
@article{Chiu2026,
author = {Chiu, Yu-Chia and Tsai, Hsin-Ju and Chen, Chia-Chang and Lin, Ying-Cheng and Lee, Shou-Wu and Lee, Teng-Yu},
title = {Predictors of Incident High-Risk Varices in Patients with Hepatitis B-Related Cirrhosis Receiving Nucleos(t)ide Analog Therapy},
journal = {Digestive Diseases},
year = {2026},
pages = {1--10},
doi = {10.1159/000553519}
}
EUVIMED